Image via Pharma Times
Last updated
UCB: Partnership
UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Source: Pharma Times
The leadership read
Alliances like this can broaden biotech & pharma commercial leadership bench strength.
Market context: This lands while the Talent Market Index reads 111.1 (Hot) — up 5.2 versus the prior month — and EMEA signal share is easing (-4.4pts).
UCB: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 17 days.
MitchelLake in this thematic
Also at UCB →
More signals across Biotech & Pharma
Partnership · EMEA
Flagship Pioneering →Flagship Pioneering announced a strategic collaboration with a Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, leveraging national health data capabilities and precision medicine expertise to support Vision 2030.
Partnership · EMEA
Thermo Fisher Scientific →Thermo Fisher Scientific awarded UK government contract: "Supply of 2 Ion Chromatography systems" — buyer: Nuclear Restoration Services Limited
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim initiated three Phase III clinical trials in precision oncology: two DAREON® programme trials (DAREON®-Lung-1 in SCLC and DAREON®-NEC-1 in epNEC) and Beamion LUNG-3 trial in HER2-mutant NSCLC. This represents advancement of biomarker-informed oncology pipeline.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Product Launch · EMEA
Amgen →European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Ma Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Intelligence powered by Autonodal ↗